Outset Medical, Inc. (OM) Stock Price & Analysis

Outset Medical, Inc. (OM) closed at USD 4.34 on Wednesday, October 28, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 4.34; the Oct 28, 2026 session ranged USD 4.16–4.4 on volume of 37,541 shares. Market capitalization is —, with a 52-week range of USD 2.84–14.25 (NMS). Source: Nexqual, retrieved October 29, 2026 at 07:10 UTC.

Also available as compact Markdown for AI agents: nexqual.com/OM.md

Key facts (OM)

• Last four reported quarters (through Jun 30, 2026): revenue $118M, net income -$74.3M (-63.1% margin), free cash flow -$38.9M (SEC filings).
• Total return with dividends: 1Y -67.8%.
• Next earnings: 2026-11-04, EPS estimate USD -0.69, revenue estimate $31.4M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (OM)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (OM)

Total return (dividends reinvested) (OM)

OM earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

OM recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

OM analyst estimates and revisions

Key Statistics (as of October 29, 2026 at 07:10 UTC)

Technical Analysis (OM)

Nexqual's technical model rates OM "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 29, 2026 at 07:10 UTC.

Earnings (OM)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 07:10 UTC.

Financials & Fundamentals (OM)

Source: Nexqual, October 29, 2026 at 07:10 UTC.

Financial Health Score (OM)

Nexqual rates Outset Medical, Inc.'s overall financial health "Mixed" across five dimensions, as of October 29, 2026 at 07:10 UTC.

Ownership (OM)

Source: Nexqual, October 29, 2026 at 07:10 UTC.

From Outset Medical, Inc.'s Latest SEC 10-K Filing (filed 2026-02-13)

Key Strengths & Strategy (as disclosed to the SEC)

• Our success depends in part on our ability to protect our proprietary technology and intellectual property rights.
• We control access to our proprietary technology by entering into confidentiality and invention assignment agreements with our employees and contractors, and confidentiality agreements with third parties.
• Our proprietary data ecosystem provides what we believe is a unique way of connecting providers and patients for real-time treatment monitoring, automated treatment documentation, and simplified compliance and record-keeping.
• Class I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA's General Controls for medical devices, which include compliance with the applicable portions of the Quality System Regulation (QSR), facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising, and promotional materials.

Partnerships

• We are operating in Mexico in collaboration with TACNA Services (TACNA), a well-known outsourced business administration service provider that provides all the back-office and facility infrastructure support, allowing us to focus on our core competencies – design and high-volume manufacturing for reliability and cost reduction.
• Pursuant to the terms of our manufacturing services agreement with TACNA (the TACNA Agreement), TACNA provides support services in connection with our manufacturing activities in Mexico.

Legal & Regulatory Risks (Item 1A, quoted)

• Changes to the reimbursement rates for dialysis treatments and measures to reduce healthcare costs may adversely impact our business.
• The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may harm our ability to set a price that we believe is fair for Tablo, our ability to generate revenue and achieve or maintain profitability, and the availability of capital.
• The FDA can also publish Safety Communications or Letters to Health Care Providers when the agency becomes aware of new issues involving a specific product or, or more broadly, a product family.
• Our products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 07:10 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt